Corixa Hands Over Bexxar® Rights to GSK

By Business Review Editor

Pharma Deals Review: Vol 2005 Issue 56 (Table of Contents)

Published: 5 Feb-2005

DOI: 10.3833/pdr.v2005.i56.726     ISSN: 1756-7874

Section: General


Corixa completed the costly purchase of Coulter Pharmaceutical in order to acquire Bexxar® for the treatment of non-Hodgkin’s lymphoma, whereby it inherited GlaxoSmithKline (GSK) as a developer for antibody therapeutic...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details